Compare iShares Silver Trust (SLV) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Silver Trust vs State Street SPDR S&P Biotech ETF — how do they compare? iShares Silver Trust trades at $54.9 (market cap $29.02B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: iShares Silver Trust is far larger — about 2.9× State Street SPDR S&P Biotech ETF's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, iShares Silver Trust nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Silver Trust for 89 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| SLV | XBI | |
|---|---|---|
Market Cap | $29.02B | $10.11B |
Volume | 16,510,334 | 12,903,266 |
52-Week High | $105.57 | $169.55 |
52-Week Low | $42.40 | $104.99 |
Typical Hold Time | 89 Days | 38 Days |
Sector | — | Broad Market / Factor |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SLV trades at $54.85, up 1.91% with bearish technical signals from moving averages but oversold RSI readings. The ETF shows minimal operational activity with $0 revenue and $2.17M net income in 2024, while assets surged to $13.4B from previous years. Recent news highlights silver's volatility amid Fed policy uncertainty and rising Treasury yields.
Outlook remains cautious due to bearish technicals and macroeconomic pressures on precious metals. Investment opportunity exists for contrarian buyers given oversold conditions, but risks include continued Fed tightening and dollar strength. Silver's dual role as monetary and industrial metal adds volatility exposure.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares Silver Trust
The ETF seeks to reflect such performance before payment of the ETF's expenses and liabilities. It is not actively managed. The ETF does not engage in any activities designed to obtain a profit from, or to ameliorate losses caused by, changes in the price of silver.
Read more on SLV →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
